Cost-effectiveness of switching from trivalent to quadrivalent inactivated influenza vaccines for the at-risk population in Italy

Francesco Saverio MenniniCentre for Economics and International Studies-Economic Evaluation and Health Technology Assessment, University of Rome, Rome, Italy;Institute for Leadership and Management in Health, Kingston University London, London, UKView further author information

Chiara BiniCentre for Economics and International Studies-Economic Evaluation and Health Technology Assessment, University of Rome, Rome, ItalyView further author information

Andrea MarcellusiCentre for Economics and International Studies-Economic Evaluation and Health Technology Assessment, University of Rome, Rome, Italy;Institute for Leadership and Management in Health, Kingston University London, London, UK;National Research Council, Institute for Research on Population and Social Policies, Rome, ItalyCorrespondence[email protected]
View further author information

Alessandro RinaldiValue & Access Country Lead, Vaccines, Sanofi s.p.a., Rome, ItalyView further author information

Elisabetta FrancoDepartment of Biomedicine and Prevention, Faculty of Medicine and Surgery, University of Rome, Rome, Italy

http://orcid.org/0000-0002-1179-4411 View further author information

Cost-effectiveness of switching from trivalent to quadrivalent inactivated influenza vaccines for the at-risk population in Italy

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Cost-effectiveness of switching from trivalent to quadrivalent inactivated influenza vaccines for the at-risk population in Italy

Citations (2)

Read on this site (2)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date